Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
GZPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $74,992,820 | $75,515,404 | $70,788,155 | $69,014,052 |
| % Growth | -0.7% | 6.7% | 2.6% | – |
| Cost of Goods Sold | $62,472,769 | $61,328,110 | $57,510,952 | $55,780,767 |
| Gross Profit | $12,520,052 | $14,187,294 | $13,277,203 | $13,233,285 |
| % Margin | 16.7% | 18.8% | 18.8% | 19.2% |
| R&D Expenses | $763,770 | $782,144 | $819,454 | $874,720 |
| G&A Expenses | $568,213 | $604,626 | $553,393 | $475,567 |
| SG&A Expenses | $2,999,918 | $3,364,740 | $6,428,832 | $6,430,356 |
| Sales & Mktg Exp. | $2,431,706 | $2,760,113 | $5,875,439 | $5,954,789 |
| Other Operating Expenses | $5,159,969 | $4,919,514 | $1,482,116 | $1,544,668 |
| Operating Expenses | $8,923,658 | $9,066,398 | $8,730,403 | $8,849,743 |
| Operating Income | $3,596,394 | $5,120,897 | $5,074,400 | $4,786,042 |
| % Margin | 4.8% | 6.8% | 7.2% | 6.9% |
| Other Income/Exp. Net | $11,186 | -$10,399 | -$31,156 | -$62,971 |
| Pre-Tax Income | $3,607,580 | $5,110,498 | $5,043,244 | $4,723,071 |
| Tax Expense | $606,849 | $851,170 | $789,874 | $754,085 |
| Net Income | $2,835,496 | $4,055,679 | $3,966,522 | $3,719,878 |
| % Margin | 3.8% | 5.4% | 5.6% | 5.4% |
| EPS | 1.74 | 2.49 | 2.44 | 2.29 |
| % Growth | -30.1% | 2% | 6.6% | – |
| EPS Diluted | 1.74 | 2.49 | 2.44 | 2.29 |
| Weighted Avg Shares Out | 1,625,858 | 1,625,791 | 1,625,791 | 1,625,791 |
| Weighted Avg Shares Out Dil | 1,625,858 | 1,625,791 | 1,625,791 | 1,625,791 |
| Supplemental Information | – | – | – | – |
| Interest Income | $404,308 | $486,336 | $626,789 | $563,867 |
| Interest Expense | $418,151 | $470,095 | $434,408 | $417,831 |
| Depreciation & Amortization | $875,243 | $929,437 | $793,656 | $720,522 |
| EBITDA | $4,900,974 | $6,458,025 | $6,271,308 | $5,760,174 |
| % Margin | 6.5% | 8.6% | 8.9% | 8.3% |